GlassScriptPhysician profile
Nancy A Goudas
NPI 1396292017
$9,233.06
in general payments reported to CMS, 2019-2025
69 companies · $2,658 in 2025
The $2,658 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,344 · 2022: $1,662 · 2023: $2,018 · 2024: $1,551 · 2025: $2,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,944 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,943.75 |
| Education | $282.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $741.16 | 2021-2025 | Piqray, Kisqali |
| Astrazeneca Pharmaceuticals LP | $586.19 | 2021-2025 | Lynparza, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $574.34 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $569.68 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $471.47 | 2021-2025 | Darzalex, Erleada, Akeega |
| Abbvie INC. | $357.09 | 2021-2025 | |
| Astellas Pharma US INC | $349.67 | 2021-2025 | Xtandi, Xospata, Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $332.47 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
| Eisai INC. | $256.37 | 2021-2025 | |
| Seagen INC. | $250.76 | 2021-2023 | Padcev, Adcetris |
| Exelixis INC. | $224.51 | 2021-2025 | Cabometyx |
| Lilly USA, LLC | $219.17 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $203.82 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $200.20 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $199.96 | 2021-2025 | Opdivo, Camzyos |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $198.71 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $189.33 | 2021-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $161.40 | 2021-2025 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $155.41 | 2021-2025 | Libtayo, Lynozyfic |
| Karyopharm Therapeutics INC. | $151.40 | 2023-2025 | Xpovio |
| Daiichi Sankyo INC. | $151.26 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Servier Pharmaceuticals LLC | $146.05 | 2021-2025 | |
| Beigene USA, INC. | $140.51 | 2023-2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $138.16 | 2021-2025 | Ojjaara, Blenrep |
| Pharmaessentia USA Corporation | $131.45 | 2023-2025 | Besremi |
| Genzyme Corporation | $130.54 | 2021-2024 | |
| Genentech USA, INC. | $120.90 | 2023-2025 | Tecentriq, Avastin, Rozlytrek |
| Deciphera Pharmaceuticals INC. | $113.81 | 2021-2025 | Qinlock |
| Sobi, INC | $111.40 | 2022-2025 | |
| Array Biopharma INC | $105.87 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Myriad Genetic Laboratories, INC. | $105.75 | 2021-2024 | Precisetumor, Myrisk |
| Celgene Corporation | $92.80 | 2022-2023 | Reblozyl, Opdualag |
| Novocure INC. | $88.90 | 2022-2024 | Optune |
| Jazz Pharmaceuticals INC. | $79.84 | 2021-2022 | |
| Beone Medicines USA, INC. | $75.98 | 2025 | Brukinsa, Tevimbra |
| Acrotech Biopharma INC. | $63.80 | 2022-2025 | Beleodaq |
| Epizyme, INC. | $58.23 | 2021-2022 | |
| Genmab U.S., INC. | $57.28 | 2023-2025 | Tivdak |
| Alexion Pharmaceuticals, INC. | $56.62 | 2024 | Ultomiris |
| Taiho Oncology, INC. | $55.54 | 2021-2025 | |
| Mirati Therapeutics, INC. | $55.22 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.81 | 2022-2024 | |
| Caris Mpi, INC. | $48.78 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $46.04 | 2022-2024 | |
| Adc Therapeutics America, INC. | $44.97 | 2022-2025 | |
| Springworks Therapeutics, INC. | $40.23 | 2025 | Ogsiveo |
| Gilead Sciences, INC. | $39.38 | 2025 | Trodelvy |
| Azurity Pharmaceuticals, INC. | $39.22 | 2025 | Danziten |
| Morphosys, US INC. | $39.16 | 2021-2023 | Monjuvi |
| Stemline Therapeutics INC. | $38.88 | 2023 | Orserdu |
| Coherus Oncology, INC. | $38.64 | 2022-2024 | |
| Celltrion USA INC. | $34.23 | 2024-2025 | Vegzelma |
| Geron Corporation | $22.32 | 2025 | Rytelo |
| Menarini Silicon Biosystems, INC. | $21.92 | 2025 | |
| Puma Biotechnology, INC. | $21.18 | 2025 | |
| Kyowa Kirin, INC. | $19.84 | 2025 | |
| Tg Therapeutics, INC. | $18.90 | 2022 | |
| Ge Healthcare | $18.10 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.16 | 2025 | Monoferric |
| Cumberland Pharmaceuticals, INC. | $17.13 | 2023 | Sancuso |
| Apellis Pharmaceuticals, INC. | $17.11 | 2025 | Empaveli |
| Tersera Therapeutics LLC | $16.86 | 2025 | Xermelo |
| Macrogenics, INC. | $16.79 | 2022 | |
| G1 Therapeutics, INC. | $16.48 | 2023 | Cosela |
| Inari Medical, INC. | $16.32 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Recordati_rare_diseases_inc. | $15.73 | 2025 | Enjaymo |
| Immunocore Limited | $15.45 | 2025 | Kimmtrak |
| Progenics Pharmaceuticals, INC. | $15.37 | 2024 | |
| Adaptive Biotechnologies Corporation | $14.04 | 2023 | Clonoseq |
Drugs and devices associated with these payments
Keytruda $383Lynparza $221Lenvima $205Kisqali $200Brukinsa $179Cabometyx $178Imbruvica $175Jakafi $165Nubeqa $163Xpovio $151Fotivda $149Xofigo $138Besremi $131Pluvicto $130Iclusig $125Darzalex $120Jaypirca $116Verzenio $116Lutathera $112Erleada $98.06Monjuvi $95.22Imfinzi $83.95Akeega $79.87Calquence $78.43Tecvayli $77.41Libtayo $75.50Niktimvo $75.04Precisetumor $73.27Tagrisso $72.55Ninlaro $70.43Tibsovo $69.97Onivyde $69.89Enhertu $69.64Scemblix $68.82Opdivo $68.31Ojjaara $67.77Fabhalta $67.11Elahere $65.28Vonjo $62.47Braftovi $61.84Mektovi $61.84Reblozyl $60.23Fruzaqla $59.24Retevmo $58.55Tivdak $57.28Padcev $57.18Ultomiris $56.62Eliquis $55.24Krazati $55.22Talvey $55.00Tecentriq $53.94Sarclisa $51.29Lorbrena $51.12Mi Cancer Seek $48.78Welireg $48.22Blenrep $47.21Lynozyfic $42.17Optune $42.00Beleodaq $41.56Balversa $40.56Ogsiveo $40.23Trodelvy $39.38Danziten $39.22Orserdu $38.88Qinlock $38.86Stivarga $37.92Vitrakvi $37.92Tevimbra $37.83Epkinly $37.22Paxlovid $35.77Somatuline Depot $35.76Idhifa $34.86Vegzelma $34.23Xtandi $32.00Tabrecta $30.85Emrelis $30.25Lonsurf $29.32Inqovi $29.32Bosulif $28.86Keytruda Qlex $28.38Injectafer $27.75Yonsa $27.35Voranigo $24.65Jevtana $23.66Udenyca $23.17Alecensa $22.92Gavreto $22.92Avastin $22.92Rozlytrek $22.92Itovebi $22.54Polivy $22.51Rytelo $22.32Cellsearch $21.92Venclexta $21.91Nerlynx $21.18Poteligeo $19.84Xospata $18.96Comirnaty $18.77Ibrance $18.77Opdualag $17.96
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Goudas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.